HEALIUS LIMITED (HLS)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

HLS - HEALIUS LIMITED

FNArena Sector : Healthcare services
Year End: June
GICS Industry Group : Health Care Equipment & Services
Index: ASX200 | ASX300 | ALL-ORDS

Healius, formerly Primary Health Care, is an Australian provider of Pathology, Diagnostic and Day Hospital services. It has been listed since 1998.

LAST PRICE CHANGE +/- CHANGE % VOLUME

$4.93

24 Sep
2021

-0.060

OPEN

$4.97

-1.20%

HIGH

$5.01

5,248,767

LOW

$4.91

TARGET
$5.093 3.3% upside
Franking for last dividend paid out: 100%
OTHER COMPANIES IN THE SAME SECTOR
EBO . SLA . CAJ . GXL . HSO . MPL . MVF . NHF . RHC . SHL . VRT . M7T . HLA . PSQ . SIL . PKS . ONT . DOC . NVL . AHX . ALC . ACL .
FNARENA'S MARKET CONSENSUS FORECASTS
HLS: 1
Title FY20
Actual		 FY21
Actual		 FY22
Forecast		 FY23
Forecast
EPS (cps) xxx 8.4 31.3 xxx
DPS (cps) xxx 13.3 16.1 xxx
EPS Growth xxx N/A 100.0% xxx
DPS Growth xxx 100.0% 21.3% xxx
PE Ratio xxx N/A 15.7 xxx
Dividend Yield xxx N/A 3.3% xxx
Div Pay Ratio(%) xxx 157.7% 51.3% xxx

Dividend yield today if purchased 3 years ago: 4.46%

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

 2.69

Estimated Dividend Growth
(Average Of Past Three Years)

  %

Amount Invested

 $ 

Tell Me The Dividend After This Many Years
Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages

Last ex-div: 13/09 - 6.75c (100%)

HISTORICAL DATA ARE ALL IN AUD
Copyright © 2021 FactSet UK Limited. All rights reserved
Title 201620172018201920202021
EPS Basic xxxxxxxxxxxxxxx8.4
DPS All xxxxxxxxxxxxxxx13.3
Sales/Revenue xxxxxxxxxxxxxxx1,900.7 M
Book Value Per Share xxxxxxxxxxxxxxx310.2
Net Operating Cash Flow xxxxxxxxxxxxxxx493.3 M
Net Profit Margin xxxxxxxxxxxxxxx3.49 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 201620172018201920202021
Return on Assets xxxxxxxxxxxxxxx1.59 %
Return on Equity xxxxxxxxxxxxxxx3.50 %
Return on Total Capital xxxxxxxxxxxxxxx7.33 %
Capex xxxxxxxxxxxxxxx61.3 M
Capex % of Sales xxxxxxxxxxxxxxx3.23 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx388.6 M

Return on Assets

Return on Equity

Return on Total Capital

Capex

Capex % of Sales

Free Cash Flow ex dividends

This is work in progress. Bear with us. It'll be amazing.

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

0.4

No. Of Recommendations

6
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Credit Suisse

xx/xx/xxxx

1

xxxxxxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Morgan Stanley

xx/xx/xxxx

3

xxxxx-xxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Ord Minnett

xx/xx/xxxx

2

xxxxxxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Morgans

31/08/2021

3

Hold

$4.71

-4.46%

Following FY21 results, Morgans adjusts FY22-24 forecasts largely due to material increases in covid testing assumptions, and increases its target price to $4.71 from $4.04.

The sale of low-margin businesses, combined with cost outs and lower tax, drove margins and improved profitability, explains the analyst.

The focus now turns towards growth, via bolt-on acquisitions, right-sizing overheads and building longer-term capabilities via the Sustainable Improvement Program (SIP) Phase II, notes Morgans.

FORECAST
Morgans forecasts a full year FY22 dividend of 13.00 cents and EPS of 23.00 cents.
Morgans forecasts a full year FY23 dividend of 15.00 cents and EPS of 26.00 cents.

Macquarie

xx/xx/xxxx

1

xxxxxxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Citi

xx/xx/xxxx

3

xxxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial
Access Stockbroker Research History >

HLS STOCK CHART

FNArena News on HLS

1
Rudi’s View: Appreciating The Mighty All-Weathers

Sep 16 2021 - Rudi's View
2
The Wrap: Oz Property, M&A, Oz Pathology, Travel Agents

Sep 10 2021 - Weekly Reports
3
FNArena Corporate Results Monitor – 31-08-2021

Aug 31 2021 - Australia
4
The Wrap: Vaccinations, Oz Banks, Consumption

Aug 06 2021 - Weekly Reports
5
Australian Broker Call *Extra* Edition – Jul 28, 2021

Jul 28 2021 - Daily Market Reports

Latest Healthcare services News

1
Funding Overhang Weighs On Ramsay’s Rebound

Jun 10 2021 - Australia
2
Treasure Chest: More Pfizer Growth For Ebos Group

May 24 2021 - Treasure Chest
3
Treasure Chest: Demand Pumps Ramsay Health

Mar 03 2021 - Treasure Chest
4
Healius Enjoying Testing Times

Dec 11 2020 - Australia
5
The First Connection

Dec 10 2020 - Weekly Reports
6
Subdued Recovery For Ramsay Health Care

Nov 16 2020 - Australia
7
Recovery Underway For Sonic Healthcare

Jun 25 2020 - Australia
8
Healius Narrows Its Focus

Jun 23 2020 - Australia
9
Short-Term Impact Likely On Ramsay Health

Mar 19 2020 - Australia
10
Rudi’s View: Focus On Quality Yield

Nov 08 2019 - Rudi's View